Last reviewed · How we verify
IL-1Ra Kineret®
At a glance
| Generic name | IL-1Ra Kineret® |
|---|---|
| Also known as | Anakinra |
| Sponsor | Adrian Parry-Jones |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- IL-1 Inhibition in Early TNBC (PHASE2)
- Empagliflozin and Anakinra for the Treatment of Postprandial Hypoglycemia in Patients With Prediabetes (PHASE2)
- ANAKINRA IN THE TREATMENT OF PEDIATRIC ACUTE MYOCARDITIS (PHASE3)
- Anakinra Pilot 2 - A Study to Optimise Dose and Route of Administration of Anakinra in Preterm Infants (PHASE2)
- A Phase 2 Trial of Anakinra for the Prevention of CAR-T Cell Mediated Neurotoxicity (PHASE2)
- Pre-emptive Anakinra for Cytokine Event Reduction (PHASE1, PHASE2)
- CORIMUNO-ANA: Trial Evaluating Efficacy Of Anakinra In Patients With Covid-19 Infection (PHASE2)
- IL-1-receptor Antagonist During Cephalic Phase of Insulin Secretion in Health and Type 2 Diabetes (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |